Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neotropix, a clinical-stage development company focused in neuroendocrine cancer treatments, has appointed Anthony Williams as its new chief medical officer.
Subscribe to our email newsletter
In this new role as CMO, Dr Williams will be responsible for patient safety, general medical governance, ethics and integrity, medical information and investigations involving human subjects relating to Neotropix’s anticancer products in clinical development.
Dr Williams joins Neotropix from Synta Pharmaceuticals, where he was vice president of medical research and part of the GlaxoSmithKline-Synta development team.
Peter Lanciano, CEO of Neotropix, said: “We are excited to have Tony as a member of the team. His depth of medical expertise, general management and business development experience in both large and small pharmaceutical and biotechnology companies, as well as his proven leadership skills make him ideally suited for this critical role within Neotropix.”